Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JJA3 | ISIN: US4576693075 | Ticker-Symbol: IM8N
Tradegate
24.04.25
16:48 Uhr
62,00 Euro
-0,50
-0,80 %
1-Jahres-Chart
INSMED INC Chart 1 Jahr
5-Tage-Chart
INSMED INC 5-Tage-Chart
RealtimeGeldBriefZeit
61,0062,0018:19
61,0061,5018:32

Aktuelle News zur INSMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INSMED Aktie jetzt für 0€ handeln
13:22Insmed kündigt Rückzahlung von 569,5 Millionen US-Dollar Wandelanleihen an5
MiInsmed Incorporated: New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis10-Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary...
► Artikel lesen
DiH.C. Wainwright maintains Buy on Insmed stock with $90 target5
17.04.INSMED Inc - 8-K, Current Report2
11.04.Cantor Fitzgerald maintains Overweight on Insmed stock, bullish on TPIP2
02.04.Insmed Incorporated (INSM): Insiders Were Dumping in Q1 20256
25.03.$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today1
19.03.Expert Outlook: Insmed Through The Eyes Of 13 Analysts4
19.03.RBC maintains Outperform on Insmed stock, price target at $1001
10.03.Insmed Incorporated: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)107BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first-...
► Artikel lesen
06.03.UBS raises Insmed stock price target to $1106
25.02.Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says3
25.02.This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday4
25.02.RBC Capital sets $100 price target on Insmed stock with Outperform rating1
24.02.FDA sets PDUFA date for Insmed's bronchiectasis drug4
21.02.UBS raises Insmed stock target to $105, maintains buy rating4
21.02.Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates2
20.02.Insmed targets $405M-$425M ARIKAYCE revenue for 2025 while advancing brensocatib and TPIP programs1
20.02.Insmed Incorporated: Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update143-ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual...
► Artikel lesen
20.02.INSMED Inc - S-8, Securities to be offered to employees in employee benefit plans-
Seite:  Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1